Water pill may be viable to test as Alzheimer's treatment as per precision medicine data dive at NIH/National Institute on Aging, published in the journal Nature Aging.
Alzheimer's disease (AD) is a neurodegenerative disease that leads to gradual memory loss and behavioral changes. It is characterized by the pathological hallmark formation of beta-amyloid plaques and the tau proteins in the brain tissues, long (almost 20 to 30 years) before the actual symptoms occur.
Can Cholesterol Lead to Alzheimer’s Disease?
Excessive cholesterol produced in specific brain cells called astrocytes could exacerbate Alzheimer's disease progression, reports reveal.
Advertisement
‘Water pill may be viable to test as Alzheimer’s treatment as per precision medicine data dive.
’
Tweet it Now
One of the most significant genetic risk factors for late-onset Alzheimer's is a form of the apolipoprotein E gene called APOE4.
A commonly used potent oral diuretic pill (approved by the U.S. Food and Drug Administration), - bumetanide, holds as a potential candidate for an Alzheimer's disease treatment (among 1,300 known FDA-approved drugs that was tested) especially among those who are at genetic risk.
![Basil may Protect Against Alzheimer’s Disease Pathology]( "Basil may Protect Against Alzheimer’s Disease Pathology")
Fenchol, the natural compound present in basil can protect the brain against Alzheimer's disease pathology. The basil compound has the same beneficial effect as gut-derived metabolites in reducing neurotoxic amyloid-beta in the brain.
Water Pill Treatment
The study team analyzed the effects of the drug through electronic health record data sets from more than 5 million people to two groups: adults over 65 who took bumetanide and a matching group who did not take bumetanide.
It was found that those who had the genetic risk and took bumetanide had a ~35% to 75% lower prevalence of Alzheimer's disease compared to those not taking the drug.
"We know that Alzheimer's disease will likely require specific types of treatments, perhaps multiple therapies, including some that may target an individual's unique genetic and disease characteristics — much like cancer treatments that are available today. The data in this paper make a good case to conduct a proof-of-concept trial of bumetanide in people with genetic risk," says Jean Yuan, M.D., Ph.D., Translational Bioinformatics and Drug Development program director in the NIA Division of Neuroscience.
The team had analyzed information of gene expression signatures from a database of 213 brain tissue samples and verified the same via both mouse and human cell experiments along with the human population. The study thereby advances a precision medicine approach for genetically greater risk individuals.
"Though further tests and clinical trials are needed, this research underscores the value of big data-driven tactics combined with more traditional scientific approaches to identify existing FDA-approved drugs as candidates for drug repurposing to treat Alzheimer's disease," says NIA Director Richard J. Hodes, M.D.
Source: Medindia
Basil may Protect Against Alzheimer’s Disease Pathology
Fenchol, the natural compound present in basil can protect the brain against Alzheimer's disease pathology. The basil compound has the same beneficial effect as gut-derived metabolites in reducing neurotoxic amyloid-beta in the brain.
Advertisement
Water Pill Treatment
The study team analyzed the effects of the drug through electronic health record data sets from more than 5 million people to two groups: adults over 65 who took bumetanide and a matching group who did not take bumetanide.
It was found that those who had the genetic risk and took bumetanide had a ~35% to 75% lower prevalence of Alzheimer's disease compared to those not taking the drug.
"We know that Alzheimer's disease will likely require specific types of treatments, perhaps multiple therapies, including some that may target an individual's unique genetic and disease characteristics — much like cancer treatments that are available today. The data in this paper make a good case to conduct a proof-of-concept trial of bumetanide in people with genetic risk," says Jean Yuan, M.D., Ph.D., Translational Bioinformatics and Drug Development program director in the NIA Division of Neuroscience.
The team had analyzed information of gene expression signatures from a database of 213 brain tissue samples and verified the same via both mouse and human cell experiments along with the human population. The study thereby advances a precision medicine approach for genetically greater risk individuals.
"Though further tests and clinical trials are needed, this research underscores the value of big data-driven tactics combined with more traditional scientific approaches to identify existing FDA-approved drugs as candidates for drug repurposing to treat Alzheimer's disease," says NIA Director Richard J. Hodes, M.D.
Source: Medindia
Genetic Similarity Between COVID-19 and Alzheimer’s Disease
Scientists have identified an anti-viral gene that affects the risk of both Alzheimer's disease and severe COVID-19.
Advertisement
 New Link Between Diabetes and Alzheimer’s Disease DiscoveredA new study explored the connection between diabetes and Alzheimer's disease as the number of Alzheimer's disease diagnoses rapidly rises with the increase in the incidence of diabetes and pre-diabetes. | Advertisement
|
Advertisement
Recommended Reading
Latest Research News
The International Space Station will be used to carry out experiments seeking to improve understanding of incurable child brain tumors and the muscle aging process.
How many people in the UK have misophonia? In a representative sample study, most people had at least some irritation upon hearing trigger sounds.
Routine eye-checkups and mass screenings enable early diagnosis and treatment of glaucoma. Late-stage glaucoma diagnosis leads to blindness.
Brain plasticity following blindness leads to superior ability in sensing signals from the heart, which has implications for bodily awareness and emotional processing.
A group of scientists were awarded Ł1.3 million to create a new “point of care testing” kit that detects Alzheimer's disease biomarkers.